Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of individually optimized doses of olmesartan medoxomil compared to
losartan in elderly and very elderly patients with essential hypertension. The study
hypothesis is non-inferiority of olmesartan medoxomil compared to losartan in lowering mean
sitting diastolic blood pressure after 12 weeks of treatment compared to baseline. The study
duration is up to 60 weeks, including a 52-week treatment period. After 12 weeks of treatment
hydrochlorothiazide may be added to control blood pressure. Efficacy and safety measurements
are carried out at up to 18 visits during the trial.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Europe, GmbH Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company